Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseas

Tuesday, August 3, 2021 1 min read

Key Takeaway: Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseas

Full Press Release Details

Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseas.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details